Indeed, our data suggest that CBX7 activity is essential for leukemic cells, regardless of their subtype, and, therefore, the antileukemic effect of CBX7 inhibition can most likely be translated to any immature hyperproliferative leukemia type. Here, CBX7 is linked to leukemia.